Substantial evidence suggests that dysfunction of the host antiviral immune response is the main cause of persistent HBV replication, and we found that TIM3 expression on CD4+ T cells was up-regulated in HCC patients with high HBV DNA load, suggesting that TIM3 may serve as a potential therapeutic target for HCC patients with high viral burden. Here, HAVCR2 is linked to hepatocellular carcinoma.